Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-T in high-risk second-line relapsed/refractory large B-cell lymphoma
2025-523806-34-00Phase 2Authorised
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glofitamab, obinutuzumab, lisocabtagene maraleucel and axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Complete response rate at end of treatment. Planned start Jul 2026; status: authorised.
02
Drugs
glofitamabobinutuzumablisocabtagene maraleucelaxicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2025-523806-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523806-34-00.